GASTROESOPHAGEAL ADENOCARCINOMA
Clinical trials for GASTROESOPHAGEAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTROESOPHAGEAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTROESOPHAGEAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Custom-Made vaccine targets cancer left behind after surgery
⭐️ VACCINE ⭐️ Recruiting nowThis early-stage trial tests a personalized cancer vaccine for people with bladder or gastroesophageal cancer who have tiny amounts of cancer still detectable after surgery. The vaccine is custom-made from each patient's unique tumor markers and aims to train the immune system to…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: ⭐️ VACCINE ⭐️
Last updated May 07, 2026 18:43 UTC
-
New drug cocktails aim to boost surgery success in stomach cancer
Disease control Recruiting nowThis study is testing new drug combinations given before and after surgery for people with advanced but removable stomach or esophageal cancer. About 100 participants will receive different experimental treatments to see if they are safe and help shrink tumors before surgery. The…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 17, 2026 00:32 UTC
-
Smart chemo: tailoring treatment for stomach cancer patients
Disease control Recruiting nowThis study tests whether adjusting chemotherapy based on how a patient's tumor responds can improve treatment for stomach or gastroesophageal junction cancer. About 20 adults with stage IB to III cancer will receive a personalized chemo plan before surgery. The goal is to see if …
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated May 17, 2026 00:30 UTC
-
New hope for stomach cancer: first human trial of BDC-4182 begins
Disease control Recruiting nowThis study tests a new drug called BDC-4182 in people with advanced stomach or gastroesophageal cancer that has spread or cannot be removed by surgery. The goal is to see if the drug is safe and shrinks tumors. About 122 participants will receive the drug alone, and researchers w…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Bolt Biotherapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
Targeted attack on hidden cancer: new trial for patients with undetectable tumor DNA
Disease control Recruiting nowThis study tests whether adding a special treatment sequence (called sequential cytoreductive intervention) to standard therapy can help people with advanced upper gastrointestinal cancers that have spread but show no detectable tumor DNA in the blood. About 54 adults with cancer…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Yale University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New Virus-Immune cell combo targets Hard-to-Treat GI cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called DISP-10 for people with advanced colorectal, stomach, or esophageal cancers that have spread. The treatment combines a virus that may help the immune system attack cancer cells with specially engineered immune cells (CAR T cells…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Dispatch Biotherapeutics • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New hope for stomach cancer: experimental drug cocktails enter human trials
Disease control Recruiting nowThis study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has gotten worse after one prior treatment. About 210 participants will receive either an experimental antibody-drug combo plus standard chemo, or sta…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 14, 2026 12:05 UTC
-
New drug duo aims to halt stomach cancer spread
Disease control Recruiting nowThis study tests whether adding a drug called zanidatamab to the usual chemotherapy can help stop advanced stomach or esophageal cancer from growing or spreading. About 168 people with HER2-positive cancer that has not responded to prior treatment will take part. The goal is to s…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
New hope for stomach cancer: experimental drug combo trial opens
Disease control Recruiting nowThis study tests whether adding new investigational drugs to standard chemotherapy and immunotherapy (pembrolizumab) can safely treat advanced stomach, gastroesophageal junction, or esophageal cancer that has not spread to other organs. About 160 adults whose cancer is HER2-negat…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:54 UTC
-
New triple-drug attack targets hard-to-treat stomach cancer
Disease control Recruiting nowThis study tests a new three-drug combination for people with advanced stomach or esophageal cancer that has spread and has specific markers (HER2 and PD-L1). About 80 participants will receive zanidatamab, pembrolizumab, and chemotherapy. The goal is to see if this combination c…
Matched conditions: GASTROESOPHAGEAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated May 07, 2026 18:42 UTC